IDEXX Laboratories director Sam Samad received new equity awards as part of his board compensation. On May 12, 2026, he was granted 234 deferred stock units, each representing a right to one share of common stock, bringing his deferred stock unit balance to 1,354 units. He also received a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share, with 525 options reported as held after the grant. Both the option and deferred stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs first. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Karen Peacock reported equity compensation awards. She received 234 deferred stock units and a non-qualified stock option covering 525 shares of common stock, both recorded as grants, not open-market purchases.
The stock option has an exercise price of $533.92 per share and expires in May 2036. Both the option and the deferred stock units vest in a single installment on the earlier of one year from grant or the 2027 annual meeting of shareholders. The deferred stock units are payable in common stock after her resignation from the board.
IDEXX Laboratories director Lawrence D. Kingsley reported multiple equity awards. On May 12, 2026, he received grants of restricted stock units covering 75 and 234 shares of common stock. Each unit represents a contingent right to receive one share.
He was also granted non-qualified stock options for 168 and 525 shares of common stock at an exercise price of $533.92 per share. According to the footnotes, these RSUs and options vest in a single installment on the one-year anniversary of the grant date or on the date of IDEXX’s 2027 annual meeting of shareholders, whichever occurs earlier. The options expire on May 11, 2036.
IDEXX Laboratories Inc. reported that director Daniel M. Junius received new equity awards. On May 12, 2026, he was granted 234 restricted stock units, each representing a contingent right to one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share.
According to the terms, both the options and the restricted stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. Following these grants, the filing shows 234 restricted stock units and 525 options from this award held directly.
IDEXX Laboratories director Joseph L. Hooley reported new equity awards. On May 12, 2026, he received 234 deferred stock units and 525 non-qualified stock options. The options have an exercise price of $533.92 per share and expire on May 11, 2036.
Both the deferred stock units and the options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are generally payable in common stock after Mr. Hooley resigns from the board.
IDEXX Laboratories director Stuart Essig reported receiving equity compensation awards. He was granted 234 restricted stock units and a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share. Both awards vest in a single installment after about one year or on the 2027 annual shareholder meeting date, whichever comes first.
IDEXX Laboratories director Bruce L. Claflin received new equity awards as part of his board compensation. He was granted 234 deferred stock units, each representing a contingent right to receive one share of common stock, bringing his deferred stock unit balance to 1,354 units.
He was also granted 525 non-qualified stock options to buy common stock at an exercise price of $533.9200 per share, all held directly. Both the options and deferred stock units vest in one installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Irene Britt Chang reported equity awards in the form of stock options and deferred stock units. She received 525 non-qualified stock options with an exercise price of $533.92 per share and 234 deferred stock units, both as compensation grants. Following these awards, she holds 753 deferred stock units and 525 stock options directly, which vest in a single installment tied to the one-year anniversary of grant or the 2027 annual shareholder meeting.
IDEXX Laboratories director Sophie V. Vandebroek reported the vesting of restricted stock units and the resulting common share holdings. On May 7, 2026, 257 restricted stock units vested and converted into 257 shares of common stock at a stated price of $0.00 per share.
After this derivative exercise, Vandebroek directly holds 905 shares of common stock and indirectly holds 8,173 shares through the Sophie V. Vandebroek Revocable Trust. The filing shows no open-market purchases or sales, only equity compensation vesting and updated ownership totals.
IDEXX Laboratories director M. Anne Szostak increased her equity exposure through a routine equity award vesting. On May 7, 2026, restricted stock units covering 257 shares of common stock converted into 257 directly held shares at an exercise price of $0.00 per share, bringing her direct common stock holdings to 519 shares. She also reports indirect ownership of 1,542 shares held by the Trust of M. Anne Szostak and 259 shares held by The O'Hanian-Szostak Family Foundation, reflecting additional positions managed through these entities.